M&A - CalciMedica, Inc.

Form Type: DEFA14A

Filing Date: 2025-06-09

Corporate Action: Merger

Type: Update

Accession Number: 000119312525137807

Filing Summary: CalciMedica, Inc. filed a definitive additional materials proxy statement supplement dated June 9, 2025, for its Annual Meeting of Stockholders scheduled for June 24, 2025. This supplement provides updates related to the merger of the Company's independent registered public accounting firm, Moss Adams LLP, with Baker Tilly US, LLP effective June 3, 2025. Following this merger, Moss Adams resigned, and the Audit Committee appointed Baker Tilly as the successor auditor. The audit report of Moss Adams for the year ending December 31, 2024, was unqualified and did not contain any adverse opinions. There have been no disagreements or reportable events with Moss Adams during the relevant periods. The supplement also clarifies that voting instructions previously submitted will remain valid unless revoked, and additional information regarding voting procedures can be found in the Proxy Statement.

Form Type: 8-K

Filing Date: 2025-06-06

Corporate Action: Merger

Type: New

Accession Number: 000119312525136297

Filing Summary: On June 3, 2025, CalciMedica, Inc. announced that its independent registered public accounting firm, Moss Adams LLP, has merged with Baker Tilly US, LLP effective June 3, 2025. As a result of this merger, Moss Adams has resigned as the auditors for CalciMedica, and Baker Tilly has been appointed as the successor independent registered public accounting firm. The audit report from Moss Adams for the financial year ending December 31, 2024, did not contain any adverse opinions or disclaimers. Furthermore, there were no disagreements with Moss Adams over accounting principles or practices during the relevant periods. The Company had not consulted with Baker Tilly regarding any accounting matters during the specified time. A letter from Moss Adams confirming these details has been filed as Exhibit 16.1 of this report.

Form Type: 10-K

Filing Date: 2025-03-27

Corporate Action: Merger

Type: Update

Accession Number: 000095017025046035

Filing Summary: CalciMedica, Inc. officially filed its annual report on Form 10-K for the fiscal year ended December 31, 2024. The company is emerging from a merger in which the formerly known Graybug Vision, Inc. completed its merger with Private CalciMedica on March 20, 2023, whereby Private CalciMedica became a wholly owned subsidiary of Graybug. Following the merger, the company was renamed CalciMedica, Inc. The report outlines the financial performance of the company, detailing significant losses anticipated in the future and the likelihood of needing substantial further funding for product development. CalciMedica highlights its reliance on clinical trials and the necessity for successful execution of strategic plans for continued market presence. It discusses general risks associated with biotechnology development, the effects of market regulations, and potential capital issues. Additionally, the number of shares outstanding as of March 21, 2025, is reported as 13,481,917. The company is classified as a non-accelerated filer and a smaller reporting company.